Suvaxyn Circo Liên Minh Châu Âu - Tiếng Croatia - EMA (European Medicines Agency)

suvaxyn circo

zoetis belgium sa - cjepivo svinjske цирковирус (inaktivirano, rekombinantni) - immunologicals for suidae, inactivated viral vaccines - svinja (za tov) - za aktivne imunizacije svinja s 3 tjedna starosti protiv svinjske цирковирус tipa 2 (pcv2) za smanjenje količine virusa u krvi i лимфоидных tkiva i fekalne prolijevanja, uzrokovane infekcijom s ЦВС2.

Ervebo Liên Minh Châu Âu - Tiếng Croatia - EMA (European Medicines Agency)

ervebo

merck sharp & dohme b.v.  - рекомбинантный virus везикулярного стоматита (soj indiana) s brisanje koverti glikoprotein, zamijenjen zair ebole (soj киквите 1995) površinski glikoprotein - Геморрагическая groznice ebole - cjepiva - ervebo is indicated for active immunization of individuals 1 year of age or older to protect against ebola virus disease (evd) caused by zaire ebola virus. korištenje ervebo moraju biti u skladu sa službenim preporukama.

Vectormune FP ILT + AE Liên Minh Châu Âu - Tiếng Croatia - EMA (European Medicines Agency)

vectormune fp ilt + ae

ceva-phylaxia co. ltd. - live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rfp-lt) and avian encephalomyelitis virus, strain calnek 1143 (ae) - immunologicals for aves, live viral vaccines, domestic fowl - piletina - for active immunisation of chickens of 8 to 13 weeks of age in order to reduce the skin lesions due to fowlpox, to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis and to prevent egg production losses due to avian encephalomyelitis.

Mhyosphere PCV ID Liên Minh Châu Âu - Tiếng Croatia - EMA (European Medicines Agency)

mhyosphere pcv id

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - svinje - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Enteroporc Coli AC Liên Minh Châu Âu - Tiếng Croatia - EMA (European Medicines Agency)

enteroporc coli ac

ceva santé animale - clostridium perfringens type c, beta1 toxoid / clostridium perfringens, type a, alpha toxoid / clostridium perfringens, type a, beta2 toxoid / escherichia coli, fimbrial adhesin f4ab / escherichia coli, fimbrial adhesin f4ac / escherichia coli, fimbrial adhesin f5 / escherichia coli, fimbrial adhesin f6 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - svinje - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce:-           clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6-           clinical signs (diarrhoea during the first days of life) associated with clostridium perfringens type a expressing alpha and beta 2 toxins-           clinical signs and mortality associated with haemorrhagic and necrotising enteritis caused by clostridium perfringens type c expressing beta1 toxin.

Suiseng Diff/A Liên Minh Châu Âu - Tiếng Croatia - EMA (European Medicines Agency)

suiseng diff/a

laboratorios hipra, s.a. - clostridioides difficile toxoid a, clostridioides difficile toxoid b, clostridium perfringens, type a, alpha toxoid - immunologicals for suidae, inactivated bacterial vaccines for pigs, clostridium - svinje - for the passive immunisation of neonatal piglets by means of the active immunisation of breeding sows and gilts:- to prevent mortality and reduce clinical signs and macroscopic lesions caused by clostridioides difficile toxins a and b. - to reduce clinical signs and macroscopic lesions caused by clostridium perfringens type a, alpha toxin.

SYNFLORIX 1 µg/0.5 mL+ 3 µg/0.5 mL+ 1 µg/0.5 mL+ 1 µg/0.5 mL+ 1 µg/0.5 mL+ 1 µg/0.5 mL+ 1 µg/0.5 mL+ 3 µg/0.5 mL+ 3 µg/0.5 mL+ 1 Bosnia và Herzegovina - Tiếng Croatia - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

synflorix 1 µg/0.5 ml+ 3 µg/0.5 ml+ 1 µg/0.5 ml+ 1 µg/0.5 ml+ 1 µg/0.5 ml+ 1 µg/0.5 ml+ 1 µg/0.5 ml+ 3 µg/0.5 ml+ 3 µg/0.5 ml+ 1

glaxosmithkline d.o.o.sarajevo - pneumokokus, prečišćeni polisaharidni диагностикум sam hemofilus utjecaj, konjugovani - suspenzija za injekciju - 1 µg/0.5 ml+ 3 µg/0.5 ml+ 1 µg/0.5 ml+ 1 µg/0.5 ml+ 1 µg/0.5 ml+ 1 µg/0.5 ml+ 1 µg/0.5 ml+ 3 µg/0.5 ml+ 3 µg/0.5 ml+ 1 µg/0.5 ml - 1doza (0,5 ml) suspenzije za injekciju sadrži: pneumokokni polisaharid serotip 11, 2 1 mikrogram pneumokokni polisaharid serotip 41, 2 3 mikrograma pneumokokni polisaharid serotip 51, 2 1 mikrogram pneumokokni polisaharid serotip 6b1, 2 1 mikrogram pneumokokni polisaharid serotip 7f1, 2 1 mikrogram pneumokokni polisaharid serotip 9v1, 2 1 mikrogram pneumokokni polisaharid serotip 141, 2 1 mikrogram pneumokokni polisaharid serotip 18c1, 3 3 mikrograma pneumokokni polisaharid serotip 19f1, 4 3 mikrograma pneumokokni polisaharid serotip 23f1, 2 1 mikrogram 1 adsorbovan na aluminijum fosfat 0,5 mg al3+ 2 konjugovan na protein d (dobijen iz netipiziranog haemophilus influenzae) kao proteinski nosač 916 mikrograma 3 konjugovan na toksoid tetanusa kao proteinski nosač 510 mikrograma 4 konjugovan na toksoid difterije kao proteinski nosač 36 mikrograma

SYNFLORIX 1 µg/0.5 mL+ 3 µg/0.5 mL+ 1 µg/0.5 mL+ 1 µg/0.5 mL+ 1 µg/0.5 mL+ 1 µg/0.5 mL+ 1 µg/0.5 mL+ 3 µg/0.5 mL+ 3 µg/0.5 mL+ 1 Bosnia và Herzegovina - Tiếng Croatia - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

synflorix 1 µg/0.5 ml+ 3 µg/0.5 ml+ 1 µg/0.5 ml+ 1 µg/0.5 ml+ 1 µg/0.5 ml+ 1 µg/0.5 ml+ 1 µg/0.5 ml+ 3 µg/0.5 ml+ 3 µg/0.5 ml+ 1

glaxosmithkline d.o.o.sarajevo - pneumokokus, prečišćeni polisaharidni диагностикум sam hemofilus utjecaj, konjugovani - suspenzija za injekciju - 1 µg/0.5 ml+ 3 µg/0.5 ml+ 1 µg/0.5 ml+ 1 µg/0.5 ml+ 1 µg/0.5 ml+ 1 µg/0.5 ml+ 1 µg/0.5 ml+ 3 µg/0.5 ml+ 3 µg/0.5 ml+ 1 µg/0.5 ml - 1doza (0,5 ml) suspenzije za injekciju sadrži: pneumokokni polisaharid serotip 11, 2 1 mikrogram pneumokokni polisaharid serotip 41, 2 3 mikrograma pneumokokni polisaharid serotip 51, 2 1 mikrogram pneumokokni polisaharid serotip 6b1, 2 1 mikrogram pneumokokni polisaharid serotip 7f1, 2 1 mikrogram pneumokokni polisaharid serotip 9v1, 2 1 mikrogram pneumokokni polisaharid serotip 141, 2 1 mikrogram pneumokokni polisaharid serotip 18c1, 3 3 mikrograma pneumokokni polisaharid serotip 19f1, 4 3 mikrograma pneumokokni polisaharid serotip 23f1, 2 1 mikrogram 1 adsorbovan na aluminijum fosfat 0,5 mg al3+ 2 konjugovan na protein d (dobijen iz netipiziranog haemophilus influenzae) kao proteinski nosač 916 mikrograma 3 konjugovan na toksoid tetanusa kao proteinski nosač 510 mikrograma 4 konjugovan na toksoid difterije kao proteinski nosač 36 mikrograma

INFANRIX IPV + Hib ≥ 30 i.j./0.5 mL+ ≥ 40 i.j./0.5 mL+ 25 µg/0.5 mL+ 25 µg/0.5 mL+ 8 µg/0.5 mL+ 40 AgU/0.5 mL+ 8 AgU/0.5 mL+ 32 Bosnia và Herzegovina - Tiếng Croatia - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

infanrix ipv + hib ≥ 30 i.j./0.5 ml+ ≥ 40 i.j./0.5 ml+ 25 µg/0.5 ml+ 25 µg/0.5 ml+ 8 µg/0.5 ml+ 40 agu/0.5 ml+ 8 agu/0.5 ml+ 32

evropa lijek pharma d.o.o. - пропорциональному protiv difterije, hemofilus utjecaj b, pertusisa, poliomijelitisa, tetanusa - prašak i suspenzija za suspenziju za injekciju - ≥ 30 i.j./0.5 ml+ ≥ 40 i.j./0.5 ml+ 25 µg/0.5 ml+ 25 µg/0.5 ml+ 8 µg/0.5 ml+ 40 agu/0.5 ml+ 8 agu/0.5 ml+ 32 agu/0.5 ml+ 10 µg/0 - 0,5 ml praška i suspenzije za suspenziju za injekciju (1 doza) sadrži: ne manje od 30 i.j. toksoid difterije, adsorbovani ne manje od 40 i.j toksoid tetanusa, adsorbovani 25 mcg toksoid pertusisa, adsorbovan 25 mcg filamentozni hemaglutinin, adsorbovan 8 mcg pertaktin 40 dantigenske jedinice poliovirus (inaktivisan) tip 1 (soj mahoney) 8 dantigenske jedinice poliovirus (inaktivisan) tip 2 (soj mef1) 32 dantigenske jedinice poliovirus (inaktivisan) tip 3 (soj saukett) 10 mcg kapsulirani polisaharid (prp) haemophilusa influenzae tip b (poliribozilribitolfosfat)

ENGERIX B za odrasle 20 µg/1 mL suspenzija za injekciju Bosnia và Herzegovina - Tiếng Croatia - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

engerix b za odrasle 20 µg/1 ml suspenzija za injekciju

evropa lijek pharma d.o.o. - hepatitis b antigen prečišćeni - suspenzija za injekciju - 20 µg/1 ml - 1 ml suspenzije za injekciju sadrži: rekombinantni površinski antigen virusa hepatitisa b (hbsag) 20 mcg